Clinical Trials Browser

Phase 2 × Rhabdomyosarcoma × Dactinomycin × Clear all

NCT01871766 2025-12-17

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Phase 2 Active not recruiting

Rhabdomyosarcoma

NCT06023641 2025-08-19

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Phase 2 Recruiting

Rhabdomyosarcoma

NCT01055314 2017-08-29

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Phase 2 Completed

175 enrolled 13 charts

Rhabdomyosarcoma, Sarcoma

NCT00003955 2014-02-14

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma

Phase 2 Completed

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma